Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced MelanomaCLINICAL CANCER RESEARCHIF10.22024-10-170PRE
International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral CentersANNALS OF SURGERYIF6.42023-04-069OA
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaCLINICAL CANCER RESEARCHIF10.22022-10-1015OA
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched AnalysisJOURNAL OF THE AMERICAN COLLEGE OF SURGEONSIF3.42021-04-0115OAAI
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T CellsCLINICAL CANCER RESEARCHIF10.22019-05-0127OAAI
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors从人胰腺肿瘤中扩增肿瘤浸润淋巴细胞 (TIL)JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62016-10-18172OAAI
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse MechanismsCLINICAL CANCER RESEARCHIF10.22012-04-30162OAAI